Tetracaine hydrochloride - Generic Drug Details

What are the generic drug sources for tetracaine hydrochloride and what is the scope of freedom to operate?

Tetracaine hydrochloride is the generic ingredient in one branded drug marketed by Alcon Labs, Bausch Lomb Ireland, and Somerset Theraps Llc, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for tetracaine hydrochloride. Eight suppliers are listed for this compound.

Summary for tetracaine hydrochloride

US Patents:	0
Tradenames:	1
Applicants:	3
NDAs:	3
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	100
Patent Applications:	4,286
What excipients (inactive ingredients) are in tetracaine hydrochloride?	tetracaine hydrochloride excipients list
DailyMed Link:	tetracaine hydrochloride at DailyMed

Recent Clinical Trials for tetracaine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hexsel Dermatology Clinic	PHASE2
Chinese PLA General Hospital	NA
Dartmouth-Hitchcock Medical Center	PHASE4

See all tetracaine hydrochloride clinical trials

Pharmacology for tetracaine hydrochloride

Drug Class	Ester Local Anesthetic
Physiological Effect	Local Anesthesia

Medical Subject Heading (MeSH) Categories for tetracaine hydrochloride

Anesthetics, Local

Anatomical Therapeutic Chemical (ATC) Classes for tetracaine hydrochloride

C05AD	Local anesthetics
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D04AB	Anesthetics for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

N01BA	Esters of aminobenzoic acid
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

S01HA	Local anesthetics
S01H	LOCAL ANESTHETICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for tetracaine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Somerset Theraps Llc	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	SOLUTION;OPHTHALMIC	217227-001	Dec 20, 2024	AB1	RX	No	No
Bausch Lomb Ireland	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	SOLUTION;OPHTHALMIC	210821-001	Mar 12, 2019	AB1	RX	Yes	Yes
Alcon Labs	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	SOLUTION;OPHTHALMIC	208135-001	Feb 29, 2016		RX	Yes	Yes

Tetracaine hydrochloride Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics of Tetracaine Hydrochloride?

Tetracaine hydrochloride is a local anesthetic used primarily for ophthalmic procedures, spinal anesthesia, and topical applications. Its market is influenced by several factors:

• Medical Applications Duration: Its widespread use in ophthalmology and minor surgical procedures sustains demand. The drug's high potency and rapid onset favor continued use over alternative local anesthetics.

• Regulatory Environment: Approval processes vary across countries. In the U.S., the FDA approved tetracaine for ophthalmic use in 1969 and for other indications in subsequent years. Regulatory restrictions or approvals impact market access and expansion.

• Market Competition: It faces competition from other local anesthetics like lidocaine and procaine. However, tetracaine's edge lies in its longer duration of action and potency for specific applications.

• Manufacturing and Patent Status: Tetracaine is generally off-patent, which has led to generic manufacturing. Price competition from generics tends to suppress margins but facilitates broader adoption.

• Emerging Technologies: Developments such as sustained-release formulations or alternatives with fewer side effects could affect demand. Currently, no significant innovative formulations have replaced tetracaine in its core applications.

• Regional Variations: Asia-Pacific and North America represent the largest markets, driven by a high volume of ophthalmic and surgical procedures. The Asia-Pacific region expects faster growth rates due to increasing healthcare infrastructure.

How Is the Financial Trajectory Shaping Up?

Financial data on tetracaine hydrochloride remain fragmented due to its status as a generic pharmaceutical, with most revenues generated from manufacturing and sales rather than proprietary sales. Key points include:

• Market Size Estimate: The global local anesthetics market was valued at approximately $1.8 billion in 2022. Tetracaine's segment accounts for an estimated 10-15% of this, translating to roughly $180-$270 million annually.

• Revenue Trends: The market remains stable with slight declines in specific regions where newer formulations or alternatives are gaining traction. Growth rates hover around 1-3% annually, mainly driven by emerging markets.

• Pricing Dynamics: Price erosion results from generic competition. In major markets, unit prices have declined 2-4% annually over the past five years.

• Profitability: Margins are low to moderate for manufacturers, with typical profit margins of 10-15%. The off-patent nature reduces R&D expenditure but increases price competition.

• Future Outlook:

  • Limited innovation suggests the market will mainly experience volume growth rather than significant revenue expansion.
  • Potential shifts could occur if reformulations improve safety or efficacy, enabling premiums.

• Impact of Regulatory Changes: Stricter regulations on compounding pharmacies and safety concerns about local anesthetics may influence market access, either constraining or expanding the market.

• Key Players: Companies like Akorn, Teva Pharmaceuticals, and Mylan dominate manufacturing, with market share concentrated among generics producers.

How Do Competitive and Regulatory Factors Affect the Market?

The competitive landscape revolves around price and formulation enhancements. No major patent protections are in place, leading to commoditization and price suppression.

Regulatory policies influence market stability:

• Enhanced safety mandates may lead to formulation restrictions.
• Approvals in emerging markets can temporarily boost volumes.
• Regulations around compounded formulations impact supply chains.

Conclusion

Tetracaine hydrochloride's market remains stable but highly competitive, with slow growth driven by generic competition and regional healthcare infrastructure expansion. Financial prospects rely heavily on volume rather than price or innovation, with margins limited by aggressive commoditization.

---

Key Takeaways

• The global market for tetracaine hydrochloride approximates $180-$270 million annually.
• Growth averages 1-3% per year, primarily through volume increases.
• Market competition is intense with no significant proprietary formulations.
• Pricing declines persist due to generic manufacturing.
• Future growth depends on regional healthcare expansion and potential reformulation innovations.

---

FAQs

1. What are the main clinical uses of tetracaine hydrochloride?
It is mainly used for ophthalmic procedures, spinal anesthesia, and topical anesthesia during minor surgeries.

2. How does tetracaine compare to other local anesthetics?
It has a longer duration of action and higher potency than procaine but competes with lidocaine, which offers similar or longer-lasting effects with different safety profiles.

3. What factors could drive growth in the tetracaine market?
Increased surgical volume, expansion into emerging markets, and potential new formulations with improved safety or extended duration.

4. How does patent status impact the market?
Being off-patent leads to widespread generic production, reducing prices and profit margins but increasing market accessibility.

5. Could regulations influence future use of tetracaine?
Yes. Stricter safety regulations or approval requirements for new formulations could either restrict or expand its market.

---

Sources:

1. Global Local Anesthetics Market Report, 2022.
2. FDA drug approvals database.
3. Company financial disclosures, 2022-2023.